Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield ND Restricted Drug Prior Au…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - North DakotaPolicy N/A

    Medicaid Expansion Restricted Use Drug Precertification List

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Dakota policy alerts

    Know when Blue Cross Blue Shield - North Dakota releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines drugs subject to precertification (prior authorization) and limited dispensing under the Medicaid Expansion program for Blue Cross Blue Shield - North Dakota; applies to providers and pharmacy/medical benefit processing for covered members.

    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyMedicaid Expansion Restricted Use Drug Precertification List
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain precertification (prior approval) for any drug listed on the Restricted Use/Precertification list before billing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~200+Listed restricted/medically administered drugs and biologics
    ~150+HCPCS/J and supply codes referenced
    MultipleIncludes J-/Q- HCPCS and A-codes for supplies
    1-833-777-5779language assistance phone number
    Pg 6/14Document pagination (partial extract)

    Coverage Criteria

    General Precertification Criteria

    Covered when precertification is obtained and benefit routing is determined according to the Preferred Drug List (PDL) and supported indications.

    General precertification criteria: Drug is listed on the Restricted Use/Precertification list AND precertification (prior authorization) approved

    Also requires FDA or compendia-supported indication for medications not explicitly on the list; consult the Preferred Drug List to determine benefit routing (pharmacy POS vs medical benefit).

    Medications that are administered by the patient or another non‑professional and do not require professional administration are generally treated as self‑administered. These products are typically processed through the pharmacy benefit at point‑of‑sale per Department of Human Services Preferred Drug List guidance rather than billed to the medical benefit. Providers should consult the Medical Policy: Medications and Diabetic Supplies Payable on the Pharmacy Benefit and the PDL to determine correct benefit routing and any precertification requirements.

    Items that are self‑administered and do not require a healthcare professional to give the drug are not typically covered under the medical benefit. Examples include continuous glucose monitor supplies coded with A4238, A4239, and A9276, which are processed through pharmacy point‑of‑sale systems per DHS Preferred Drug List. Verify coverage and routing on the PDL and the referenced Medical Policy before submitting medical claims.

    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyMedicaid Expansion Restricted Use Drug Precertification List
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain precertification (prior approval) for any drug listed on the Restricted Use/Precertification list before billing.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Billing CodesProvider Actions and Authorization RequirementsQuantity Limits and Supply RulesSite of Care NotesBiosimilar MentionsBackgroundDefinitions

    Medications administered by an individual that do not require professional administration are considered self‑administered and therefore are generally excluded from the medical benefit. Such items should be billed and adjudicated through the pharmacy benefit unless otherwise specified on the Precertification Drug List or by prior authorization guidance.

    Coding and Billing Codes

    Listed HCPCS/J/Q Codes and corresponding drugs (partial extract)HCPCS
    J3262TOCILIZUMAB (ACTEMRA IV)
    Q2055IDCABTAGENE VICLEUCEL (ABECMA)
    J0791CRIZANLIZUMAB-TMCA (ADAKVEO)
    J9042BRENTUXIMAB (ADCETRIS)
    J9029NADOFARAGENE FIRADENOVEC-VNCG (ADSTILADRIN)
    J7171ADAMTS13 RECOMBINANT-KRHN (ADZYNMA)
    J1931LARONIDASE (ALDURAZYME)
    J1552IMMUNE GLOBULIN (HUMAN) IV (ALYGLO)
    Q5126BEVACIZUMAB-MALY (ALYMSYS)
    J1426CASIMERSEN (AMONDYS-45)
    1–10 of 15
    1/2
    A-codes for continuous glucose monitoring supplies/servicesHCPCS
    A4238Supply allowance for adjunctive continuous glucose monitor (CGM), includes all supplies and accessories, month supply = 1 unit of service
    A4239Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply unit of service
    A9276Ambulatory continuous glucose monitoring via subcutaneous sensor for minimum of 72 hours; physician office provided equipment and associated services
    Noted drug J-codes (partial list)HCPCS
    J9223ZIIHERA
    J9276ZINPLAVA
    Jo565ZIRABEV
    Q5118ZYNLONTA
    J9359ZYNTEGLO
    J3393ZYNYZ
    J9345
    Codes and supply codes referencedmixed
    95250Ambulatory continuous glucose monitoring via subcutaneous sensor for minimum 72 hours; office provided equipment; sensor placement; hook-up; calibration; training; removal; printout
    A4238Supply allowance for adjunctive continuous glucose monitor (CGM), month supply = 1 unit
    A4239Supply allowance for non-adjunctive, non-implanted CGM, 1 month supply unit
    A9276Sensor; invasive (subcutaneous), disposable, for use with interstitial CGM system
    A9277Transmitter; external, for use with interstitial continuous glucose monitoring system
    A9278Receiver (monitor); external, for use with interstitial continuous glucose monitoring system
    E2102Adjunctive continuous glucose monitor or receiver
    E2103Non-adjunctive, non-implanted continuous glucose monitor or receiver
    J0139Injection, adalimumab, 20 mg (Humira)
    J0364Injection, apomorphine hydrochloride (Apokyn)
    1–10 of 94
    1/10
    inv-09: CGM sensor minimum duration — minimum of 72 hours
    Minimum durationContinuous glucose monitor sensor must be in place for a minimum of 72 hours
    Relevant codeA9276 — ambulatory continuous glucose monitoring via subcutaneous sensor for minimum of 72 hours
    Processing noteCGM supplies/services processed through pharmacy point-of-sale per DHS Preferred Drug List where applicable
    inv-10: Sensor unit definition — 1 unit = 1 supply day
    Sensor unit definitionOne unit = one supply day (sensor; invasive, subcutaneous, disposable)
    Usage contextApplies to CGM supply codes (A4238, A4239) and sensor code (A9276) for monthly and daily supply accounting
    Processing noteSupply unit definitions align with Department of Human Services Preferred Drug List processing

    Provider Actions and Authorization Requirements

    Prior Authorization

    Precertification / Prior Approval Required

    Precertification (prior authorization) is required for medications listed on the Restricted Use / Precertification Drug List (brands and generics). For drugs not on the list, FDA- or compendia-supported indications are required. Consult BCBSND Prior Authorization resources and the Preferred Drug List to determine benefit routing (medical vs pharmacy) and submission requirements.

    • Precertification required for listed medical drugs and equivalents; consult Prior Authorization resources
    • FDA or compendia-supported indications required for medications not on the list
    • Both brand and generic equivalents require precertification
    Billing Rule

    J-code Listing — Check Authorization

    Multiple HCPCS / J-codes are referenced in this policy for injectable drugs and biologics. Verify authorization requirements and include J-code(s) on prior authorization requests to ensure correct processing and to avoid denials.

    • Provider action: Check Authorization for applicable J-codes before billing
    • Examples include (partial list): J0139, J0364, J0593, J0596–J0599, J1000, J1071–J1072, J1110, J1290, J1438, J1748, J1595
    Billing Rule

    CGM Supplies — Processing and Codes

    Continuous glucose monitoring (CGM) supplies and related codes are processed through the pharmacy benefit per Department of Human Services direction. Confirm processing route and include appropriate supply codes on requests or claims.

    • A4238 — Supply allowance for adjunctive CGM, month = 1 unit
    • A4239 — Supply allowance for non-adjunctive, non-implanted CGM, month = 1 unit
    • A9276 — Sensor; invasive, disposable, one unit = 1 supply day
    • A9277 — Transmitter; external
    • A9278 — Receiver (monitor); external
    • E2102 — Adjunctive CGM or receiver
    • E2103 — Non-adjunctive, non-implanted CGM or receiver
    Note

    Language Assistance Contact

    Language assistance is available to providers and members. Contact the BCBSND language services line for free interpreter services.

    • Provider action: Offer language assistance when needed
    • Members/providers: Call 1-833-777-5779 (TTY 1-800-366-6888 or 711)
    Denial Risk

    Provider Actions — None Otherwise Stated / Denial Risk

    No additional provider actions or denial triggers are explicitly stated in this section beyond those above. Providers should follow prior authorization guidance, include required codes, and confirm benefit routing (medical vs pharmacy) to reduce risk of claim denial.

    • No other specific denial triggers stated in this section
    • Follow PA requirements and include required documentation and codes to avoid denials

    Quantity Limits and Supply Rules

    inv-28: Continuous glucose monitor supplies — quantity limit (1)
    Quantity limit (monthly)Continuous glucose monitor supplies — limit 1 unit per month
    Applies toAdjunctive and non-adjunctive CGM supplies processed via A4238/A4239/A9276
    RoutingProcessed through pharmacy point-of-sale per DHS Preferred Drug List guidance
    inv-29: A4238/A4239/A9276 (CGM sensors/supplies) — 1 unit per day (sensor: one unit = 1 supply day); monthly supply = 1 unit
    Per-day allowanceA4238/A4239/A9276 — 1 unit per day (sensor: one unit = 1 supply day); monthly supply counted as 1 unit
    Codes referencedA4238 (adjunctive supply), A4239 (non-adjunctive supply), A9276 (sensor)
    Processing noteSupplies and accessories included in the supply allowance; processed through pharmacy POS per DHS PDL

    Site of Care Notes

    Billing Rule

    Bill office/ambulatory codes for CGM services

    Use ambulatory/office setting professional service codes when billing for CGM placement, sensor placement, calibration, patient training and related professional services.

    • Example code for office-based CGM services: CPT 95250 (office-provided equipment and associated services).

    Biosimilar Mentions

    Billing Rule

    Bill Wezlana (ustekinumab-auub) as listed biosimilar

    Ustekinumab-auub (Wezlana) is listed as a biosimilar formulation in the policy code list and should be billed using the corresponding Q-code.

    • Biosimilar code listed: Q5137 (ustekinumab-auub, Wezlana).
    Billing Rule

    Bill Pyzchiva (ustekinumab-ttwe) as listed biosimilar

    Ustekinumab-ttwe (Pyzchiva) is listed as a biosimilar formulation in the policy code list and should be billed using the corresponding Q-code.

    • Biosimilar code listed: Q9996 (ustekinumab-ttwe, Pyzchiva).

    Background

    This policy is an administrative listing of medications and associated billing codes that require precertification (prior approval) under the Medicaid Expansion benefit. It identifies medical‑administered drugs subject to prior authorization and also specifies codes for supplies that are processed via pharmacy point‑of‑sale, including continuous glucose monitor supplies (A4238, A4239, A9276). Providers must obtain precertification where required and follow the Preferred Drug List and applicable policy links for benefit routing and dispensing limits.

    Definitions

    inv-24: Medical Drug — A drug that is covered under the medical benefit and requires precertification (prior approval).
    DefinitionMedical Drug — A drug that is covered under the medical benefit and requires precertification (prior approval).
    Precertification referencePrior authorizations information available via BCBSND Policies & Prior_Authorization links in the policy document
    Benefit routing noteMedical drugs requiring precertification are administered under the medical benefit unless processed through pharmacy per PDL
    inv-25: Preferred Drug List (PDL) — List of medications preferred and processed by pharmacy point-of-sale systems; consult for additional precertification requirements and benefit routing.
    DefinitionPreferred Drug List (PDL) — List of medications preferred and processed by pharmacy point-of-sale systems; consult for additional precertification requirements and benefit routing.
    UsageUse the most recent PDL to determine whether a medication or diabetic supply is processed via pharmacy POS or medical benefit
    LinkPDL information referenced in the policy for routing and precertification details
    inv-26: Sensor unit — Sensor; invasive (subcutaneous), disposable, for use with interstitial continuous glucose monitoring system — one unit = 1 supply day.
    DefinitionSensor unit — Sensor; invasive (subcutaneous), disposable, for use with interstitial continuous glucose monitoring system — one unit = 1 supply day.
    Associated codesApplies to A9276 (sensor) and supply codes A4238/A4239 for supply accounting
    ImplicationOne sensor unit equals one day of supply when calculating daily/monthly limits
    inv-27: Language assistance services — Free spoken and written language support for members who do not speak English or prefer another language.
    ServiceLanguage assistance services — Free spoken and written language support for members who do not speak English or prefer another language.
    ContactCall 1-833-777-5779 or TTY 1-800-366-6888 / 711 for language assistance (multilingual notices included in policy).
    ScopeMultilingual notices in the document indicate availability of free language services for members in multiple languages.